|
[1] Parkin DM, Bray F, Ferlay J, et al.Global cancer statistics, 2002[J].CA Cancer J Clin, 2005, 55 (2) :74-108.
|
|
[2]Yuen MF, Hou JL, Chutaputti A.Hepatocellular carcinoma inthe Asian pacific region[J].J Gastroenterol Hepatol, 2009, 24 (3) :346-353.
|
|
[3]Papatheodoridis GV, Manolakopoulos S, Touloumi G, et al.Virological suppression does not prevent the development ofhepatocellular carcinoma in HBeAg-negative chronic hepati-tis B patients with cirrhosis receiving oral antiviral (s) startingwith lamivudine monotherapy:results of the nationwideHEPNET.Greece cohort study[J].Gut, 2011, 60 (8) :1109-1116.
|
|
[4]Venook AP, Papandreou C, Furuse J, et al.The incidenceand epidemiology of hepatocellular carcinoma:a global andregional perspective[J].Oncologist, 2010, 15 (Suppl 4) :S5-S13.
|
|
[5]Yang JD, Roberts LR.Hepatocellular carcinoma:A global view[J].Nat Rev Gastroenterol Hepatol, 2010, 7 (8) :448-458.
|
|
[6]El-Serag HB.Epidemiology of hepatocellular carcinoma inUSA[J].Hepatol Res, 2007, 37 (Suppl 2) :S88-S94.
|
|
[7]Chang MH, Chen CJ, Lai MS, et al.Universal hepatitis Bvaccination in Taiwan and the incidence of hepatocellular car-cinoma in children.Taiwan Childhood Hepatoma Study Group[J].N Engl J Med, 1997, 336 (26) :1855-1859.
|
|
[8]Yuen MF, Hou JL, Chutaputti A.Hepatocellular carcinoma inthe Asian Pacific region.[J]Gastroenterol Hepatol, 2009, 24 (3) :346-353.
|
|
[9] Di Marco V, Lo Iacono O, CammàC, et al.The long-termcourse of chronic hepatitis B[J].Hepatology, 1999, 30 (1) :257-264.
|
|
[10]Singal AG, Volk ML, Jensen D, et al.A sustained viral re-sponse is associated with reduced liver-related morbidityand mortality in patients with hepatitis C virus[J].Clin Gas-troenterol Hepatol, 2010, 8 (3) :280-288.
|
|
[11]Marrero J, Fontana R, Fu S, et al.Alcohol, tobacco and o-besity are synergistic risk factors for hepatocellular carcinoma[J].J Hepatol, 2005, 42 (2) :218-224.
|
|
[12]Tanabe KK, Lemoine A, Finkelstein DM, et al.Epidermal growthfactor gene functional polymorphism and the risk of hepatocellularcarcinoma in patients with cirrhosis[J].JAMA, 2008, 299 (1) :53-60.
|
|
[13]Poon RT, Fan ST, Ng IO, et al.Different risk factors and prog-nosis for early and late intrahepatic recurrence after resection ofhepatocellular carcinoma[J].Cancer, 2000, 89 (3) :500-507.
|
|
[14]Llovet JM, Schwartz M, Mazzaferro V.Resection and livertransplantation for hepatocellular carcinoma[J].Semin LiverDis, 2005, 25 (2) :181-200.
|
|
[15]芮静安, 刘振文.原发性肝癌外科治疗的理性思考[J].传染病信息, 2009, 22 (2) :69-72.
|
|
[16]陆荫英, 陈艳, 冯永毅.肝癌冷冻治疗的临床研究进展[J].传染病信息, 2009, 22 (2) :123-126.
|
|
[17]Lu DS, Yu NC, Raman SS, et al.Percutaneous radiofrequencyablation of hepatocellular carcinoma as a bridge to liver trans-plantation[J].Hepatology, 2005, 41 (5) :1130-1137.
|
|
[18]Gish RG, Porta C, Lazar L, et al.Phase III randomized con-trolled trial comparing the survival of patients with unresect-able hepatocellular carcinoma treated with nolatrexed ordoxorubicin[J].J Clin Oncol, 2007, 25 (21) :3069-3075.
|
|
[19]Yeo W, Mok TS, Zee B, et al.A randomized phase III studyof doxorubicin versus cisplatin/interferon alpha-2b/doxoru-bicin/fluorouracil (PIAF) combination chemotherapy for unr-esectable hepatocellular carcinoma[J].J Natl Cancer Inst, 2005, 97 (20) :1532-1538.
|
|
[20]Edeline J, Raoul JL, Vauleon E, et al.Systemic chemother-apy for hepatocellular carcinoma in non-cirrhotic liver:a ret-rospective study[J].World J Gastroenterol, 2009, 15 (6) :713-716.
|
|
[21]Barbare JC, BouchéO, Bonnetain F, et al.Randomized controlledtrial of tamoxifen in advanced hepatocellular carcinoma[J].J ClinOncol, 2005, 23 (19) :4338-4346.
|
|
[22]Nowak A, Findlay M, Culjak G, et al.Tamoxifen for hepato-cellular carcinoma[J].Cochrane Database Syst Rev, 2004, (3) :CD001024.
|
|
[23]Mazzaferro V, Romito R, Schiavo M, et al.Prevention of hepa-tocellular carcinoma recurrence with alpha-interferon after liverresection in HCV cirrhosis[J].Hepatology, 2006, 44 (6) :1543-1554.
|
|
[24]Qin S, Bai Y, Ye S, et al.Phase III study of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) versus doxorubicin aspalliative systemic chemotherapy in advanced HCC in Asianpatients[J].J Clin Oncol, 2010, 28 (Suppl) :S15.
|
|
[25]Avila MA, Berasain C, Sangro B, et al.New therapies forhepatocellular carcinoma[J].Oncogene, 2006, 25 (27) :3866-3884.
|
|
[26]Greten TF, Korangy F, Manns MP, et al.Molecular therapyfor the treatment of hepatocellular carcinoma[J].Br J Canc-er, 2009, 100 (1) :19-23.
|
|
[27]Cook KM, Figg WD.Angiogenesis inhibitors:current strate-gies and future prospects[J].CA Cancer J Clin, 2010, 60 (4) :222-243.
|
|
[28] Slamon DJ, Leyland-Jones B, Shak S, et al.Use of chem-otherapy plus a monoclonal antibody against HER2 for meta-static breast cancer that overexpresses HER2[J].N Engl JMed, 2001, 344 (11) :783-792.
|
|
[29] Tsao MS, Sakurada A, Cutz JC, et al.Erlotinib in lung canc-er-molecular and clinical predictors of outcome[J].N EnglJ Med, 2005, 353 (2) :133-144.
|
|
[30]Flaherty KT, Puzanov I, Kim KB, et al.Inhibition of mutated, activated BRAF in metastatic melanoma[J].N Engl J Med, 2010, 363 (23) :809-819.
|
|
[31]Yau T, Chan P, Epstein R, et al.Management of advancedhepatocellular carcinoma in era of targed therapy[J].LiverInternational, 2009, 29 (1) :10-17.
|
|
[32]Witjes CD, Verhoef C, Verheul HM, et al.Syetemic treat-ment in hepatocellular carcinoma;“a small step for man…”[J].Neth J Med, 2009, 67 (3) :86-90.
|
|
[33]Lencioni R, Marrero J, Venook A, et al.Design and rationalefor the non-interventional Global Investigation of therapeuticDEcisions in hepatocellular carcinoma and of its treatmentwith sorafeNib (GIDEON) study[J].Int J Clin Pract, 2010, 64 (8) :1034-1041.
|
|
[34] Yang Y, Lu Y, Wang C, et al.Cryotherapy is associated withimproved clinical outcomes of sorafenib therapy for advancedhepatocellular carcinoma[J].Cell Biochemistry Biophys, 2012, 63 (2) :159-169.
|
|
[35]Bruix J, Llovet JM.Major achievements in hepatocellular carci-noma[J].Lancet, 2009, 373 (9664) :614-616.
|
|
[36]栗光明, 冷希圣.肝癌及其治疗[J].传染病信息, 2009, 22 (2) :115-118.
|
|
[37]Hornberg JJ, Bruggeman FJ, Westerhoff HV, et al.Cancer:a Systems Biology disease[J].Biosystems, 2006, 83 (2-3) :81-90.
|
DownLoad: